The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
Academic rigour, journalistic flair
Articles on A-beta
Displaying all articles
After the failure of multiple drug trials the outlook for an Alzheimer’s drug is bleak. This shouldn’t be a surprise. We don’t know the cause or even how to diagnose the disease.
Not all drug development needs to start from scratch. Sometimes researchers discover that a drug developed for one disease can be used for another. Here a cancer drug may show promise for dementia.
Many pieces leading to Alzheimer’s disease have been identified. To put the pieces together, one scholar argues that the government should launch a Manhattan Project-scale effort to find a cure.
